Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Dipeptidyl-peptidase I precursor | 0.0088 | 0.2084 | 0.2084 |
Trypanosoma cruzi | cysteine peptidase C (CPC), putative | 0.0154 | 0.6157 | 1 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0154 | 0.6157 | 0.6157 |
Plasmodium falciparum | dipeptidyl aminopeptidase 1 | 0.0217 | 1 | 1 |
Plasmodium falciparum | dipeptidyl aminopeptidase 2 | 0.0217 | 1 | 1 |
Leishmania major | cysteine peptidase C (CPC),CPC cysteine peptidase, Clan CA, family C1, Cathepsin B-like | 0.0054 | 0 | 0.5 |
Giardia lamblia | Dipeptidyl-peptidase I precursor | 0.0088 | 0.2084 | 0.2084 |
Trichomonas vaginalis | Clan CA, family C1, cathepsin B-like cysteine peptidase | 0.0138 | 0.516 | 1 |
Schistosoma mansoni | dipeptidyl-peptidase I (C01 family) | 0.0217 | 1 | 1 |
Echinococcus multilocularis | cathepsin b | 0.0154 | 0.6157 | 0.5 |
Echinococcus multilocularis | cathepsin b | 0.0154 | 0.6157 | 0.5 |
Trypanosoma brucei | cysteine peptidase C (CPC) | 0.0054 | 0 | 0.5 |
Brugia malayi | cathepsin B-like cysteine proteinase | 0.0154 | 0.6157 | 0.5 |
Giardia lamblia | Encystation-specific protease | 0.0088 | 0.2084 | 0.2084 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0154 | 0.6157 | 0.6157 |
Schistosoma mansoni | SmCB2 peptidase (C01 family) | 0.0154 | 0.6157 | 0.6157 |
Toxoplasma gondii | cathepsin CPC2 | 0.0088 | 0.2084 | 0.2084 |
Toxoplasma gondii | cathepsin CPC1 | 0.0217 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0154 | 0.6157 | 1 |
Plasmodium vivax | dipeptidyl aminopeptidase 1, putative | 0.0217 | 1 | 1 |
Plasmodium vivax | dipeptidyl aminopeptidase 2, putative | 0.0217 | 1 | 1 |
Echinococcus granulosus | cathepsin b | 0.0154 | 0.6157 | 0.5 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0154 | 0.6157 | 0.6157 |
Echinococcus granulosus | cathepsin b | 0.0154 | 0.6157 | 0.5 |
Toxoplasma gondii | preprocathepsin c precursor, putative | 0.0217 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.